pomalidomide has been researched along with Lymphoma, Primary Effusion in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Astter, Y; Davis, DA; Lurain, K; Ramaswami, R; Shrestha, P; Wang, HW; Yarchoan, R; Yuan, CM; Zhou, T | 1 |
| Aisabor, AI; Davis, DA; Jaeger, HK; Shrestha, P; Stream, A; Yarchoan, R | 1 |
| Gottwein, E; Manzano, M; Patil, A | 1 |
| Chaudhary, PM; Gopalakrishnan, R; Matta, H; Tolani, B; Triche, T | 1 |
4 other study(ies) available for pomalidomide and Lymphoma, Primary Effusion
| Article | Year |
|---|---|
Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.
Topics: Antibodies, Monoclonal; Cytotoxicity, Immunologic; Humans; Lymphoma, Primary Effusion; Tretinoin | 2023 |
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Topics: Angiogenesis Inhibitors; B7-2 Antigen; Gene Expression Regulation, Neoplastic; Humans; Intercellular Adhesion Molecule-1; Lymphoma, Primary Effusion; Signal Transduction; T-Lymphocytes; Thalidomide; Tumor Cells, Cultured | 2021 |
CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Topics: Casein Kinase Ialpha; Cell Line, Tumor; CRISPR-Cas Systems; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Primary Effusion; Molecular Targeted Therapy; Neoplasm Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Knockdown Techniques; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Primary Effusion; Mice; Nuclear Proteins; Peptide Hydrolases; Proto-Oncogene Proteins c-myc; Thalidomide; Transcription Factors; Triazoles; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2016 |